Background:
In 2017, Danish pharma company Novo Nordisk launched a drug called Ozempic to help manage type 2 diabetes. But the drug, semaglutide, came with a pretty unexpected bonus: it suppressed hunger signals. Suddenly, that block of Caramilk in the pantry was just... forgettable.
Novo Nordisk quickly realised the side effect of this diabetes drug might actually be a bigger business than its original purpose. Then came the celebrity endorsements, the TikToks, the before-and-afters.
In 2021, the FDA approved a higher-dose version called Wegovy specifically for weight loss, and adoption exploded.
By late 2025, one in eight US adults were taking a GLP-1 drug, and the US obesity rate had fallen from 39.9% to 37%, roughly 7.6 million fewer people living with obesity.
Where we're at today:
The emergence of these drugs are facing entire industries to rethink their strategies.
Food: Household snack spending drops 5 to 11% within six months of starting a GLP-1. EY-Parthenon estimates up to $12 billion in lost snack sales over the next decade. So, Big Food is pivoting: Nestle launched Vital Pursuit frozen meals for GLP-1 users, and General Mills rolled out high-protein Cheerios.
Airlines: The four biggest US carriers could save up to $580 million a year in fuel costs as passengers get lighter. Lighter humans, lighter planes, smaller fuel bill.
Gyms: Since up to 40% of GLP-1 weight loss can be muscle, it meant that gyms went from panic-stations to launching dedicated GLP-1 protocols. The new pitch isn't "lose weight", it's more like "don't lose your muscle while you do".
Where to from here:
Novo Nordisk and Eli Lilly pulled in a combined $40 billion USD in GLP-1 revenue in 2024 and analysts reckon the party's just getting started. The global GLP-1 market is forecast to hit $150 billion by 2030, with Pfizer, Amgen and Viking Therapeutics all racing to develop rival drugs.
The structural losers are becoming clear:
The winners:
For thirty years, obesity was treated as a willpower problem. Now, for the first time, millions of people aren't fighting hunger every day.
And that means these drugs haven't just shrunk waistlines, they've shrunk the junk food industry's revenue too.
Sign up for Flux and join 100,000 members of the Flux family
